The latest drug recalls just add to a long line of scandals that have tainted the pharma sector of India
The Gambian tragedy has raised uncomfortable questions about drug regulation in India. The Truth Pill is a depressing but eye-opening reality check of the regulatory landscape
Objective of drug regulation is to ensure safety, efficacy, and quality of drugs
Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms
After the anti-diabetic market, India's cardiac market in for a shake-up
Lack of near-term visibility on profitability for the core business is another concern about Indian firm
Discovered in 1970, the drug was tested on severe Covid-19 patients on DCGI's direction
CSL Behring's Hemgenix, administered just once, cut the number of bleeding events expected over the course of a year by 54%, a key study of the therapy found
Siddharth Mittal, CEO & MD, Biocon, elaborates on his plans to grow this business further
First phase is expected early next fiscal year; CBIC in talks with six major concerned regulatory agencies with the vast majority of export matters
Sales declining anyway and there is no need to ban because of alleged misuse, say experts
The industry is divided on the issue of phasing out codeine-based cough syrups, which are used by many as intoxicants
As part of de-risking their business, they have started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio
Drugs for ailments like chronic kidney disease, some high end antibiotics, anti-virals (anti-infectives), as well as some cancer drugs are likely to be brought under trade margin rationalization first
Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%
Swiggy announced on Friday that it has extended its 'Future of Work' policy and announced a permanent work-from-anywhere for majority of roles.
Leading drug makers Sun Pharma and Glenmark are recalling products in the US, the world's largest market for medicines, due to lapses in the manufacturing process. As per the latest enforcement report by the US Food and Drug Administration (USFDA), a US-based unit of Sun Pharma is recalling 50,680 vials of Testosterone Cypionate Injection, used to treat low testosterone in adult males, in the American market. According to the US health regulator, the Mumbai-based drug major is recalling the affected lot due to "water leakage" leading to deviation from current good manufacturing practices (cGMP). The company is also recalling 27 vials of the same medication due to cGMP deviations, USFDA said. "Manufacturing deviations were reported due to an abnormal appearance on parts of machinery," it added. The affected lot was produced at Sun Pharma's Halol (Gujarat) based manufacturing plant. New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the company, initiated the Class II ...
In a Q&A, Rehan A Khan talks about his firm's strong focus on R&D and its commitment to making drugs affordable
The Union Ministry of Health has made amendments to the Drugs Rules, 1945, to implement this
US President Joe Biden is set to meet with infant formula manufacturers as his administration works to ease nationwide shortages by importing foreign supplies